PT738512E - Utilizacao de um inibidor da hmg-coa-reductase para evitar um segundo ataque cardiaco - Google Patents

Utilizacao de um inibidor da hmg-coa-reductase para evitar um segundo ataque cardiaco

Info

Publication number: PT738512E
Authority: PT; Portugal
Prior art keywords: heart attack; reductase inhibitor; hmg; coa; avoid
Prior art date: 1995-04-19

Application number

PT96106104T

Other languages

English (en)

Inventor

John C Alexander

Adeoye Y Olukotun

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-04-19

Filing date

1996-04-18

Publication date

2003-11-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23684677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT738512(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-04-18 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2003-11-28 Publication of PT738512E publication Critical patent/PT738512E/pt

Links

229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 2
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title abstract 2
208000010125 myocardial infarction Diseases 0.000 title abstract 2
239000005541 ACE inhibitor Substances 0.000 abstract 1
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 abstract 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 abstract 1
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 1
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 abstract 1
229960002965 pravastatin Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

PT96106104T 1995-04-19 1996-04-18 Utilizacao de um inibidor da hmg-coa-reductase para evitar um segundo ataque cardiaco PT738512E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/424,984 US5622985A (en)	1990-06-11	1995-04-19	Method for preventing a second heart attack employing an HMG CoA reductase inhibitor

Publications (1)

Publication Number	Publication Date
PT738512E true PT738512E (pt)	2003-11-28

Family

ID=23684677

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT96106104T PT738512E (pt)	1995-04-19	1996-04-18	Utilizacao de um inibidor da hmg-coa-reductase para evitar um segundo ataque cardiaco

Country Status (10)

Country	Link
US (1)	US5622985A (pt)
EP (1)	EP0738512B1 (pt)
JP (1)	JPH08291082A (pt)
AT (1)	ATE244006T1 (pt)
AU (1)	AU715181B2 (pt)
CA (1)	CA2172884A1 (pt)
DE (1)	DE69628874T2 (pt)
DK (1)	DK0738512T3 (pt)
ES (1)	ES2202393T3 (pt)
PT (1)	PT738512E (pt)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0708771B1 (en) *	1993-07-15	1998-10-07	Pfizer Inc.	Benzyloxyquinuclidines as substance p antagonists
US5994348A (en)	1995-06-07	1999-11-30	Sanofi	Pharmaceutical compositions containing irbesartan
KR100213895B1 (ko) *	1996-10-14	1999-08-02	박원훈	감귤류 과피 추출물, 이로부터 분리 정제된 헤스페리딘 또는 나린진을 포함하는 심혈관 질환 예방및 치료제 조성물
US6180660B1 (en)	1997-08-26	2001-01-30	Merck & Co., Inc.	Cholesterol-lowering therapy
EP1007019A2 (en) *	1997-08-26	2000-06-14	Merck & Co., Inc.	Cholesterol-lowering therapy
EP1514543A1 (en)	1997-08-29	2005-03-16	Pfizer Inc.	Combination therapy comprising atorvastatin and an antihypertensive agent
GT199800127A (es) *	1997-08-29	2000-02-01		Combinaciones terapeuticas.
US6147109A (en) *	1997-10-14	2000-11-14	The General Hospital Corporation	Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
US6180597B1 (en)	1998-03-19	2001-01-30	Brigham And Women's Hospital, Inc.	Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
ES2242398T3 (es) *	1998-06-05	2005-11-01	Warner-Lambert Company Llc	Estabilizacion de composiciones que contienen inhibidores de la enzima de conversion de la angiotensina utilizando oxido de magnesio.
JP2002518448A (ja) *	1998-06-24	2002-06-25	メルクエンドカムパニーインコーポレーテッド	高血中コレステロールを治療する組成物および方法
US6423751B1 (en)	1998-07-14	2002-07-23	The Brigham And Women's Hospital, Inc.	Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
US7141602B2 (en) *	1998-09-18	2006-11-28	Lek Pharmaceuticals D.D.	Process for obtaining HMG-CoA reductase inhibitors of high purity
SK288117B6 (sk) *	1998-11-20	2013-09-03	Skyepharma Canada Inc.	Rapidly dispersing solid dry therapeutic dosage form
AU2007200367B2 (en) *	1999-02-06	2010-04-08	Astrazeneca Ab	Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
GB0001662D0 (en)	1999-02-06	2000-03-15	Zeneca Ltd	Pharmaceutical compositions
SE9903028D0 (sv) *	1999-08-27	1999-08-27	Astra Ab	New use
PL353199A1 (en) *	1999-08-30	2003-11-03	Aventis Pharma Deutschland Gmbh	Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
EP1216037A2 (en) *	1999-09-21	2002-06-26	Emory University	Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents
ES2328446T5 (es)	2000-02-04	2014-02-27	Children's Hospital Research Foundation	Uso de lipasa ácida lisosomal para tratar la aterosclerosis y enfermedades asociadas
WO2001058443A1 (fr) *	2000-02-10	2001-08-16	Takeda Chemical Industries, Ltd.	INHIBITEURS DE TNF-$g(a)
AU2001256278A1 (en) *	2000-04-18	2001-10-30	Bayer Aktiengesellschaft	Use of cse inhibitors for treating heart failure
US6689807B1 (en) *	2000-06-08	2004-02-10	Caritas St. Elizabeth's Medical Center Of Boston, Inc.	HMG CoA reductase inhibitors for promoting angiogenesis
US8586094B2 (en) *	2000-09-20	2013-11-19	Jagotec Ag	Coated tablets
WO2002024193A1 (en) *	2000-09-20	2002-03-28	Skyepharma Canada Inc.	Stabilised fibrate microparticles
US6982251B2 (en)	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
IL156445A0 (en) *	2001-01-26	2004-01-04	Schering Corp	Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en)	2001-01-26	2006-07-04	Schering Corporation	Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US20060287254A1 (en) *	2001-01-26	2006-12-21	Schering Corporation	Use of substituted azetidinone compounds for the treatment of sitosterolemia
AR035533A1 (es)	2001-01-26	2004-06-02	Schering Corp	Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
US20020183383A1 (en) *	2001-02-27	2002-12-05	Rene Belder	Pharmaceutical compositions
US6458769B1 (en)	2001-06-25	2002-10-01	Astrazeneca Ab	Amorphous compound
US6627760B1 (en)	2001-06-25	2003-09-30	Astrazeneca Ab	Amorphous compound
US6462174B1 (en)	2001-06-25	2002-10-08	Astrazeneca Ab	Amorphous compound
US6576256B2 (en)	2001-08-28	2003-06-10	The Brigham And Women's Hospital, Inc.	Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6669955B2 (en) *	2001-08-28	2003-12-30	Longwood Pharmaceutical Research, Inc.	Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US7053080B2 (en) *	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
MXPA04002573A (es)	2001-09-21	2004-06-18	Schering Corp	Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
US7107198B2 (en) *	2001-11-02	2006-09-12	Sun Microsystems, Inc.	Automatic generation of reduced-size circuit models including inductive interaction
DK3072978T3 (en)	2002-05-09	2018-09-17	Brigham & Womens Hospital Inc	: 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER
AR040588A1 (es) *	2002-07-26	2005-04-13	Schering Corp	Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
US20060019269A1 (en) *	2002-10-17	2006-01-26	Decode Genetics, Inc.	Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US20080293750A1 (en) *	2002-10-17	2008-11-27	Anna Helgadottir	Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
WO2004043457A1 (en)	2002-11-06	2004-05-27	Schering Corporation	Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
CA2510319A1 (en)	2002-12-20	2004-07-15	Thomas J. Smith	High pressure compaction for pharmaceutical formulations
US20040168951A1 (en) *	2003-02-27	2004-09-02	Mackie Robert W.	Method and system for self administration of medications
JP2006519869A (ja)	2003-03-07	2006-08-31	シェーリング　コーポレイション	置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
US7459442B2 (en) *	2003-03-07	2008-12-02	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
EP1601668B1 (en) *	2003-03-07	2008-08-27	Schering Corporation	Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
CA2517572C (en) *	2003-03-07	2011-12-13	Schering Corporation	Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
MXPA05009848A (es) *	2003-03-17	2005-12-06	Japan Tobacco Inc	Composiciones farmaceuticas de inhibidores de la proteina de transferencia del ester de colesterilo.
WO2004082675A1 (en) *	2003-03-17	2004-09-30	Japan Tobacco Inc.	Method for increasing the oral bioavailability of s-[2- ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate
TWI494102B (zh) *	2003-05-02	2015-08-01	Japan Tobacco Inc	包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
EP1636365B1 (en) *	2003-06-05	2010-08-04	National University Of Singapore	Cholesterol biosynthesis pathway modulators and uses thereof
NZ544784A (en) *	2003-07-28	2009-11-27	Reddys Lab Inc Dr	Treatment and prevention of cardiovascular events using a beta-adrenergic receptor antagonist, a diuretic, an inhibitor of HMG CoA reductase, an inhibitor of the rennin-angiotensin system and asprin; wherein acidic and basic components are separated.
EP1510208A1 (en) *	2003-08-22	2005-03-02	Fournier Laboratories Ireland Limited	Pharmaceutical composition comprising a combination of metformin and statin
US6978908B2 (en) *	2003-09-15	2005-12-27	Gerber Products Company	Drinking vessel with adjustable handles
US20100216863A1 (en) *	2004-01-30	2010-08-26	Decode Genetics Ehf.	Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
US8158362B2 (en) *	2005-03-30	2012-04-17	Decode Genetics Ehf.	Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
ES2282062T1 (es)	2004-06-04	2007-10-16	Teva Pharmaceutical Industries Ltd.	Composicion farmaceutica que contiene irbesartan.
US7803838B2 (en) *	2004-06-04	2010-09-28	Forest Laboratories Holdings Limited	Compositions comprising nebivolol
US9164104B2 (en)	2004-10-06	2015-10-20	The Brigham And Women's Hospital, Inc.	Relevance of achieved levels of markers of systemic inflammation following treatment
WO2006083779A2 (en) *	2005-01-31	2006-08-10	Mylan Laboratories, Inc.	Pharmaceutical composition comprising hydroxylated nebivolol
AP2896A (en)	2005-05-31	2014-05-31	Mylan Lab Inc	Compositions comprising nebivolol
US20070037797A1 (en) *	2005-08-15	2007-02-15	Hellstrom Harold R	Method of reducing the risk of adverse cardiovascular (CV) events associated with the administration of pharmaceutical agents which favor CV events
WO2007030375A2 (en) *	2005-09-08	2007-03-15	Children's Hospital Medical Center	Lysosomal acid lipase therapy for nafld and related diseases
US8119358B2 (en) *	2005-10-11	2012-02-21	Tethys Bioscience, Inc.	Diabetes-related biomarkers and methods of use thereof
US20070116756A1 (en) *	2005-11-23	2007-05-24	Dr. Reddy's Laboratories Limited	Stable pharmaceutical compositions
ES2300188B1 (es) *	2006-05-24	2009-05-01	Ferrer Internacional, S.A.	Comprimido bicapa para la prevencion de los accidentes cardiovasculares.
EP2302395B1 (en)	2006-06-07	2015-04-15	Health Diagnostic Laboratory, Inc.	Markers associated with arteriovascular events and methods of use thereof
US10568860B2 (en) *	2006-08-30	2020-02-25	Kowa Co., Ltd.	Pharmaceutical composition containing statin-encapsulated nanoparticle
US20080118572A1 (en) *	2006-10-10	2008-05-22	Harold Richard Hellstrom	Methods and compositions for reducing the risk of adverse cardiovascular events associated with the administration of artificial blood
WO2008124121A1 (en) *	2007-04-06	2008-10-16	Scidose, Llc	Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
WO2008124122A1 (en) *	2007-04-09	2008-10-16	Scidose, Llc	Combinations of statins and anti-obesity agent and glitazones
EP2131835A1 (en) *	2007-04-09	2009-12-16	Scidose, Llc	Combinations of statins and anti-obesity agent
TW200849035A (en)	2007-04-18	2008-12-16	Tethys Bioscience Inc	Diabetes-related biomarkers and methods of use thereof
TW201201764A (en)	2010-02-01	2012-01-16	Hospital For Sick Children	Remote ischemic conditioning for treatment and prevention of restenosis
KR20130040851A (ko)	2010-03-31	2013-04-24	더 호스피탈 포 식 칠드런	심근 경색 후 결과를 개선시키기 위한 원격 허혈 처치의 사용
KR20130040878A (ko)	2010-04-08	2013-04-24	더 호스피탈 포 식 칠드런	외상성 손상을 위한 원격 허혈 처치의 사용
US9107983B2 (en)	2010-10-27	2015-08-18	Warsaw Orthopedic, Inc.	Osteoconductive matrices comprising statins
US8877221B2 (en)	2010-10-27	2014-11-04	Warsaw Orthopedic, Inc.	Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9308190B2 (en)	2011-06-06	2016-04-12	Warsaw Orthopedic, Inc.	Methods and compositions to enhance bone growth comprising a statin
ES2786506T3 (es)	2012-08-01	2020-10-13	Zahra Tavakoli	Composiciones congeladas fluidas que comprenden un agente terapéutico
SG10201604814WA (en)	2013-03-21	2016-08-30	Eupraxia Pharmaceuticals USA LLC	Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
MX2018005035A (es)	2015-10-27	2018-09-06	Eupraxia Pharmaceuticals Inc	Formulaciones de liberacion sostenida de anestesicos locales.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX7065E (es) *	1980-06-06	1987-04-10	Sankyo Co	Un procedimiento microbiologico para preparar derivados de ml-236b
DE3536687A1 (de) *	1985-10-15	1987-04-16	Hoechst Ag	Verfahren zur behandlung von atherosklerose, thrombose und der peripheren gefaesskrankheit
US4920123A (en) *	1988-10-21	1990-04-24	Beyer Jr Karl H	Method for controlling and/or lowering serum triglyceride and/or cholesterol levels in mammals
US5008284A (en) *	1989-02-15	1991-04-16	E. R. Squibb & Sons, Inc.	Method of reducing pre- and post-ischemic myocardial arrhythmias and fibrillation
CA2042526A1 (en) *	1990-06-11	1991-12-12	Adeoye Y. Olukotun	Method for preventing a second heart attack employing an hmg coa reductase inhibitor

1995
- 1995-04-19 US US08/424,984 patent/US5622985A/en not_active Expired - Lifetime
1996
- 1996-03-28 CA CA002172884A patent/CA2172884A1/en not_active Abandoned
- 1996-04-18 DK DK96106104T patent/DK0738512T3/da active
- 1996-04-18 EP EP96106104A patent/EP0738512B1/en not_active Revoked
- 1996-04-18 ES ES96106104T patent/ES2202393T3/es not_active Expired - Lifetime
- 1996-04-18 PT PT96106104T patent/PT738512E/pt unknown
- 1996-04-18 AU AU50741/96A patent/AU715181B2/en not_active Ceased
- 1996-04-18 AT AT96106104T patent/ATE244006T1/de not_active IP Right Cessation
- 1996-04-18 DE DE69628874T patent/DE69628874T2/de not_active Revoked
- 1996-04-19 JP JP8098084A patent/JPH08291082A/ja active Pending

Also Published As

Publication number	Publication date
DE69628874T2 (de)	2004-04-22
CA2172884A1 (en)	1996-10-20
JPH08291082A (ja)	1996-11-05
DK0738512T3 (da)	2003-10-06
AU5074196A (en)	1996-10-31
ES2202393T3 (es)	2004-04-01
EP0738512A1 (en)	1996-10-23
ATE244006T1 (de)	2003-07-15
DE69628874D1 (de)	2003-08-07
US5622985A (en)	1997-04-22
AU715181B2 (en)	2000-01-20
EP0738512B1 (en)	2003-07-02

Publication	Publication Date	Title
PT738512E (pt)	2003-11-28	Utilizacao de um inibidor da hmg-coa-reductase para evitar um segundo ataque cardiaco
BR9908690A (pt)	2000-12-05	Composição farmacêutica contendo estatina e aspirina
CA2040865A1 (en)	1991-11-16	Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
BR9915267A (pt)	2001-12-04	Métodos de tratamento, prevenção ou redução derisco de doença de alzheimer
NO20002172L (no)	2000-07-04	FremgangsmÕte for behandling av hyperkolesterolemi med usubstituert polydiallylamin
ES2123177T3 (es)	1999-01-01	Preparacion de absorcion percutanea que contiene buprenorfina.
IE970731A1 (en)	2000-10-04	Product and method for the treatment of hyperlipidemia
CA2222303A1 (fr)	1997-05-01	Utilisation d'au moins un inhibiteur de no-synthase dans le traitement des peaux sensibles
SE9103701D0 (sv)	1991-12-13	Apolipoprotein
DE69317880D1 (de)	1998-05-14	Biochemische reinigung von simvastatin
DE69719931D1 (de)	2003-04-24	Verwendung von Acetylcystein zur Herstellung eines Arzneimittels zur Behandlung von chronischen Geschwüren
EP0773022A3 (de)	1999-05-12	Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden, enthaltend Sympthomimeticum und Pantothenol und/oder Pantothensäure
IT1283225B1 (it)	1998-04-16	Ceppi di batteri, composizione farmaceutica contenente uno o piu' di tali ceppi e uso dei medesimi per la prevenzione e la terapia delle
WO1999009967B1 (en)	1999-07-08	Cholesterol-lowering therapy
WO2000047196A3 (en)	2001-03-15	Use of statins for treating viral infections
AU5544994A (en)	1994-05-24	Use of 17alpha-dihydroequilenin for lowering cholesterol
BR9810616A (pt)	2000-09-12	Inibidores de farnesil transferase em combinação com inibidores de hmg coa redutase para o tratamento do cancer
MY122052A (en)	2006-03-31	Method of treating tourette''s syndrome
BG103635A (en)	2001-08-31	Method for the re-esterification of esters of alpha-ketocarbonic acids
CA2061907A1 (en)	1992-09-02	Treatment of ocular hypertension with a synergistic combination
WO2001044144A3 (en)	2001-11-15	Process for the preparation of sodium salts of statins
AU7500200A (en)	2001-04-30	Combined therapies for atherosclerosis treatment
BR0007901A (pt)	2001-10-30	Método para a preservação ou redução deeventos cardiovasculares associados comintervenção coronária
DE69724793D1 (de)	2003-10-16	Ethen enthaltende lösungen sowie deren verwendung in heil- und vorbeugeverfahren
BR9704686A (pt)	2000-06-06	Grupos de bactérias e composição farmacêutica contendo tais grupos, e uso da mesma para impedir e tratar doenças associadas com, ou causadas pelo metabolismo alterado de ácido de bìlis.